NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Qlaris Bio

Qlaris Bio

Private
Dedham, MassachusettsHealthcare & Life Scienceshttps://qlaris.bio/

Last Round

Seed Round

Jun 17, 2026

Total Funding Raised

$49M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Qlaris Bio is a biotechnology company that develops innovative, first-in-class therapies for serious and debilitating ophthalmic diseases, with a primary focus on glaucoma and ocular hypertension.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

glaucoma treatmentophthalmic drugsintraocular pressureIOPbiotech startupclinical-stage biotechocular hypertensionsmall-molecule drugfixed-dose combinationFDCophthalmology pipelineepiscleral venous pressuredrug developmentclinical trialseye health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Qlaris Bio Comps

Public and private peers based on sector, stage, and business model.

Qlaris Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Qlaris Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJun 17, 2026
Series BApr 30, 2024
Series AAug 1, 2019

Key People

Founding team and executive leadership

FARVO Barbara Wirostko

Co-Founder And Chief Medical Officer

Founding Team

Thurein Htoo

Chief Executive Officer Co-Founder

Founding Team

David Neafus

CFO

Executive Team

Qlaris Bio Investors

Notable investors and investment history

Qlaris Bio investors
InvestorRounds
New Leaf Venture PartnersSeries B, Series A
abrdn Inc.Series B
Mayo Clinic VenturesSeries B
Canaan PartnersSeries B, Series A
AberdeenSeries B
Mayo Clinic VenturesSeries B
Correlation VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Raised $4M in a Seed Round.

  • Mar 1, 2026

    Fred Guerard appointed as new President and CEO.

Qlaris Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Qlaris Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Qlaris Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersDedham, Massachusetts
Employee Range11
Year Founded2019
Last FundingJun 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.